Targeting Focal Adhesion Kinase Suppresses the Malignant Phenotype in Rhabdomyosarcoma Cells.

Another explanation is that there may be significant differences between cell lines that have the signature PAX-FOXO1 fusion (SJCRH30) [18] and those that do not (RD), which would actually be an important finding because those tumors are the most aggressive and difficult to treat.

also in 13,097 other papers

The time for tumor tripling was increased in the Y15-treated tumors compared with vehicle-treated tumors but did not reach statistical significance (5.1 ± 1.8 days vs 6.3 ± 1.3 days, NS, vehicle vs Y15).

also in 111,027 other papers